First-line (1L) Encorafenib + Cetuximab + mFOLFOX6 in East Asian Patients with BRAF V600E-mutant Metastatic Colorectal Cancer (mCRC): Results From The Phase 3 BREAKWATER Study
Web preview is not available
Try directly downloading the file.